Review Article
Flow Cytometric Detection of the Classical Hodgkin Lymphoma: Clinical and Research Applications
Figure 2
Clinical cases of CHL can demonstrate varying proportions of HRS cells rosetted by CD5+ T cells that also increase the apparent CD45 expression level of the rosetted HRS cells. Representative examples of flow cytometric immunophenotyping of lymph nodes involved by CHL using the single tube, 9-color assay are shown. HRS cells (shown in red and emphasized) are identified by their expression of CD30, CD40, CD95, absence of expression of CD64, and increased side light scatter (SSC-H) compared to normal lymphocytes; all remaining viable events are in blue. Oblique and horizontal arrows denote rosetted and unrosetted HRS populations, respectively. Dot plots at the end of panels demonstrate HRS cells in isolation for clarity. (a) Neoplastic unrosetted HRS cells have expression of low CD45, intermediate CD30, and bright CD40 and CD95, without expression of CD64 (position of negative determined by isotype-matched control experiment, data not shown), CD5, CD15 (data not shown), or CD20 (data not shown). The small, T-rosetted population of HRS has increased CD45 and expression of CD5 (oblique arrow). (b) Neoplastic unrosetted HRS cells have expression of intermediate CD45, intermediate to bright CD30, CD40 (data not shown) and CD95 (data not shown), and intermediate CD15, without expression of CD5, CD64, or CD20. The small rosetted population has expression of CD5 and increased CD45. (c) Neoplastic unrosetted HRS cells have expression of low to intermediate CD45, variable intermediate to bright CD30, bright CD40 (data not shown) and CD95, intermediate CD15, and variable CD71 (data not shown), without expression of CD5, CD64, or CD20 (data not shown). The rosetted population has increased CD45 and expression of CD5. (© Modified from 2009 American Society of Clinical Pathology [10]).
